Glycomimetics, Inc.
Records under this name other than the patents Glycomimetics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 24 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,518,896 | Treatment of cancers of the blood using selected glycomimetic compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,291,678 | Methods for the Treatment And/Or Prevention of Cardiovascular Disease by Inhibition of E-Selectin Formerly held In force · High confidence | In force | High confidence | |
| US 11,433,086 | Combination of T-Cell Checkpoint Inhibitors with Inhibitors of E-Selectin or CXCR4, or with Heterobifunctional Inhibitors of Both E-Selectin and CXCR4 Lapsed on the fee record Ended Sep 6, 2026 · High confidence | Lapsed on the fee record | Ended Sep 6, 2026 | High confidence |
| US 7,989,601 | Heterobifunctional pan-selectin inhibitors Term ended Term ended Sep 1, 2026 · From the USPTO record | Term ended | Term ended Sep 1, 2026 | From the USPTO record |
| US 7,361,644 | Specific antagonist for both E- and P-selectins Term ended Term ended Apr 14, 2026 · From the USPTO record | Term ended | Term ended Apr 14, 2026 | From the USPTO record |
| US 8,633,303 | Heterobifunctional pan-selectin inhibitors Lapsed on the fee record Ended Jan 21, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 21, 2026 | From the USPTO record |
| US 11,197,877 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists Lapsed on the fee record Ended Dec 14, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 14, 2025 | From the USPTO record |
| US 9,796,745 | E-selectin antagonist compounds, compositions, and methods of use Lapsed on the fee record Ended Oct 24, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 24, 2025 | From the USPTO record |
| US 11,045,485 | Glycomimetic inhibitors of PA-IL and PA-IIL lectins Lapsed on the fee record Ended Jun 29, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 29, 2025 | From the USPTO record |
| US 8,410,066 | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors Lapsed on the fee record Ended Apr 2, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 2, 2025 | From the USPTO record |